NIPER Develops a New Drug For Type II Diabetes
The National Institute of Pharmaceutical Education and Research, Ahmedabad (NIPER-A), claims to have developed a new class of compounds for […]
Say something
Tags: ahmedabad, Association of Commonwealth Universities, chemical molecules, diabetes, Director, education, health, Health/Medical/Pharmaceuticals, India, Kiran Kalia, manufacturing, manufacturing process, MB Institute of Mental Health, medicine, mohali, MS, National Institute of Pharmaceutical Education, National Institute of Pharmaceutical Education and Research, Patent Filing, Rifampicin, strain, TB, tuberculosis, Type-II diabetes
New norms for MNC drug prices
In a move that would prevent MNCs such as GlaxoSmithKline (GSK), Eli Lilly, Roche and Pfizer from selling their drugs at a huge premium in India, the government may soon finalise norms for monitoring prices of costly imported patented medicines for diseases such as diabetes, arthritis, obesity, cancer and heart diseases.
Govt to provide INR 100 cr to pharma industry
With a view to promote research and development in the pharmaceutical sector, the government plans to provide soft loans of INR 100 crore to the industry in the current fiscal.
-
-
Flipkart Health+ App Launched
06-04-2022
